High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.
BACKGROUND: High expression of the RNA-binding protein RBM3 has previously been found to be associated with good prognosis in breast cancer, ovarian cancer, malignant melanoma and colorectal cancer. The aim of this study was to examine the prognostic impact of immunohistochemical RBM3 expression in prostate cancer. FINDINGS: Immunohistochemical RBM3 expression was examined in a tissue microarray
